Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Ehrnrooth · SciRah

Researcher profile · Semantic Scholar

E. Ehrnrooth

Share profile

E. Ehrnrooth — researcher profile on SciRah

h-index: 21
Works: 82
Citations: 2,487

Most-cited papers

Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease
R. Zachariae, C. G. Pedersen, A. B. Jensen, E. Ehrnrooth +2 more
2003British Journal of Cancer610 citations Open access
Semantic Scholar
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
J. Machiels, R. Haddad, J. Fayette, L. Licitra +15 more
2015The Lancet Oncology377 citations
Semantic Scholar
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T. Seiwert, J. Fayette, D. Cupissol, J. D. del Campo +7 more
2014Annals of Oncology179 citations Open access
Semantic Scholar
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
J. Kjeldsen, C. Lorentzen, E. Martinenaite, E. Ellebaek +13 more
2022Nature Medicine161 citations Open access
Semantic Scholar
The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification
J. Jou, K. Harrington, M. Zocca, E. Ehrnrooth +1 more
2020Clinical Cancer Research141 citations Open access
Semantic Scholar
The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
Michael R. Horsman, E. Ehrnrooth, M. Ladekarl, Jens Overgaard
1998International Journal of Radiation Oncology, Biology, Physics94 citations
Semantic Scholar
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
E. Cohen, L. Licitra, B. Burtness, J. Fayette +18 more
2017Annals of Oncology77 citations Open access
Semantic Scholar
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer
Nicola Steele, A. Anthony, M. Saunders, B. Esmarck +5 more
2012British Journal of Cancer76 citations Open access
Semantic Scholar
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
G. Goss, E. Felip, M. Cobo, Shun Lu +19 more
2018JAMA Oncology54 citations Open access
Semantic Scholar
Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks.
Ulf Simonsen, E. Ehrnrooth, L. U. Gerdes, Ole Færgemann +3 more
1991Clinical science46 citations
Semantic Scholar
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
P. Clement, T. Gauler, J. Machiels, R. Haddad +15 more
2016Annals of Oncology43 citations Open access
Semantic Scholar
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
C. Lorentzen, J. Kjeldsen, E. Ehrnrooth, M. Andersen +1 more
2023Journal for ImmunoTherapy of Cancer42 citations Open access
Semantic Scholar
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
C. Lorentzen, E. Martinenaite, J. Kjeldsen, R. Holmstroem +5 more
2022Frontiers in Immunology41 citations Open access
Semantic Scholar
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
S. Gadgeel, G. Goss, J. Soria, E. Felip +15 more
2017Lung Cancer39 citations Open access
Semantic Scholar
Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer.
E. Ehrnrooth, C. Grau, R. Zachariae, Jørn Andersen
2001Acta oncologica38 citations Open access
Semantic Scholar
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
B. Burtness, R. Haddad, J. Dinis, J. Trigo +24 more
2019JAMA Oncology37 citations Open access
Semantic Scholar
Symptom and Quality of Life Improvement in LUX‐Lung 8, an Open‐Label Phase III Study of Second‐Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First‐Line Platinum‐Based Chemotherapy
E. Felip, V. Hirsh, S. Popat, M. Cobo +12 more
2018Clinical Lung Cancer35 citations Open access
Semantic Scholar
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
J. Vermorken, S. Rottey, E. Ehrnrooth, K. Pelling +3 more
2013Annals of Oncology34 citations Open access
Semantic Scholar
Rectal cancer survival in the Nordic countries and Scotland
J. Folkesson, G. Engholm, E. Ehrnrooth, A. Kejs +9 more
2009International Journal of Cancer32 citations
Semantic Scholar
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
J. Kjeldsen, C. Lorentzen, E. Martinenaite, E. Ellebaek +13 more
2021Nature Medicine29 citations Open access
Semantic Scholar
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
M. Schuler, L. Paz-Ares, L. Sequist, V. Hirsh +12 more
2019Lung Cancer28 citations Open access
Semantic Scholar
A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover.
D. Cupissol, T. Seiwert, J. Fayette, E. Ehrnrooth +3 more
201319 citations
Semantic Scholar
The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells.
N. Hornung, K. Stengaard-Pedersen, E. Ehrnrooth, T. Ellingsen +1 more
2000Clinical and Experimental Rheumatology18 citations
Semantic Scholar
Effect of induced hypercholesterolemia in rabbits on functional responses of isolated large proximal and small distal coronary arteries.
Ulf Simonsen, D. Prieto, M. J. Mulvany, E. Ehrnrooth +2 more
1992Arteriosclerosis and Thrombosis A Journal of Vascular Biology17 citations Open access
Semantic Scholar
An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).
J. Machiels, S. Subramanian, Á. Ruzsa, G. Répássy +6 more
2010Journal of Clinical Oncology15 citations
Semantic Scholar
Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
Ezra E. W. Cohen, L. Licitra, J. Fayette, T. Gauler +16 more
201514 citations
Semantic Scholar
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
B. Burtness, R. Haddad, J. Dinis, J. Perez +16 more
201712 citations
Semantic Scholar
Survival of patients with Stage III colon cancer is improved in hereditary non‐polyposis colorectal cancer compared with sporadic cases. A Danish registry based study
L. Brixen, I. Bernstein, S. Bülow, E. Ehrnrooth
2013Colorectal Disease12 citations
Semantic Scholar
Third-line therapy for metastatic colorectal cancer
M. G. Gundgaard, J. Soerensen, E. Ehrnrooth
2007Cancer Chemotherapy and Pharmacology12 citations
Semantic Scholar
The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo.
E. Ehrnrooth, H. von der Maase, B. Sørensen, J. Poulsen +1 more
1999International Journal of Radiation Biology12 citations
Semantic Scholar
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
N. Jørgensen, J. Kaae, J. Grauslund, Ö. Met +7 more
2021Cancers11 citations Open access
Semantic Scholar
LBA29_PRAFATINIB VERSUS METHOTREXATE (MTX) AS SECOND-LINE TREATMENT FOR PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WHO PROGRESSED AFTER PLATINUM-BASED THERAPY: PRIMARY EFFICACY RESULTS OF LUX-HEAD & NECK 1, A PHASE III TRIAL
J. Machiels, R. Haddad, J. Fayette, L. Licitra +16 more
201411 citations Open access
Semantic Scholar
1349PSubsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
L. Sequist, Y.-L. Wu, M. Schuler, T. Kato +13 more
201710 citations Open access
Semantic Scholar
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
Shun Lu, Wei Li, Cai-Cun Zhou, Cheng-Ping Hu +9 more
2018OncoTargets and Therapy9 citations Open access
Semantic Scholar
LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.
J. Machiels, L. Licitra, R. Haddad, M. Tahara +4 more
20129 citations
Semantic Scholar
LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
B. Burtness, J. Bourhis, J. Vermorken, Luyan Dai +3 more
20129 citations
Semantic Scholar
A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
T. Seiwert, J. Fayette, D. Cupissol, J. DelCampo +8 more
20129 citations Open access
Semantic Scholar
Increased Thymidylate Synthase mRNA Concentration in Blood Leukocytes following an Experimental Stressor
E. Ehrnrooth, R. Zacharia, Gunner Svendsen, M. M. Jørgensen +4 more
2002Psychotherapy and Psychosomatics9 citations
Semantic Scholar
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
K. Skak, H. Søndergaard, K. S. Frederiksen, E. Ehrnrooth
2009Cytokine8 citations
Semantic Scholar
102PLUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung
C.-H. J. Yang, G. Goss, E. Felip, Shun Lu +6 more
20176 citations Open access
Semantic Scholar
P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS
K. Park, E. Tan, K. O'Byrne, Lan-Jun Zhang +13 more
20175 citations Open access
Semantic Scholar
PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology
L. Sequist, Yong-Jian Wu, M. Schuler, T. Kato +14 more
20175 citations Open access
Semantic Scholar
P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
G. Goss, E. Felip, M. Cobo, Shun Lu +17 more
20174 citations Open access
Semantic Scholar
A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls.
E. Ehrnrooth, B. Sørensen, P. Meldgaard, N. Hornung +2 more
2000Clinica chimica acta; international journal of clinical chemistry4 citations
Semantic Scholar
Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.
N. Jørgensen, J. Kaae, J. Grauslund, Ö. Met +5 more
2020Journal of Clinical Oncology3 citations
Semantic Scholar
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung
G. Goss, K. Lee, E. Felip, M. Cobo +14 more
20163 citations Open access
Semantic Scholar
Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil.
E. Ehrnrooth, B. L. Sørensen, J. Poulsen, B. Sørensen +1 more
2000Acta oncologica3 citations Open access
Semantic Scholar
1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
J. Riess, E. Cohen, J. Spicer, P. Shaw +8 more
2023Annals of Oncology2 citations Open access
Semantic Scholar
An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.
J. Spicer, M. Provencio, P. G. Lopez, J. Bosch-Barrera +11 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders
S. Gadgeel, J. Soria, E. Felip, M. Cobo +16 more
20172 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Gibson×9
Invite
N. Gibson — researcher profile on SciRah
Shun Lu×9
Invite
Shun Lu — researcher profile on SciRah
J. Fayette×8
Invite
J. Fayette — researcher profile on SciRah
M. Tahara×8
Invite
M. Tahara — researcher profile on SciRah

×8

Invite

J. Vermorken — researcher profile on SciRah

Invite

E. Cohen — researcher profile on SciRah

Invite

F. Solca — researcher profile on SciRah

J. D. del Campo×7

Invite

J. D. del Campo — researcher profile on SciRah

Invite

G. Goss — researcher profile on SciRah

Invite

P. Clement — researcher profile on SciRah

Invite

X. Cong — researcher profile on SciRah

Invite

M. Andersen — researcher profile on SciRah